paliperidone

Ligand id: 7258

Name: paliperidone

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: paliperidone

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 69.81
Molecular weight 426.21
XLogP 2.98
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat psychotic or manic symptoms of schizophrenia.
In November 2014, the US FDA granted a supplemental New Drug Application (sNDA) for paliperidone palmitate (PubChem CID 9852746) as a treatment for schizoaffective disorder as either monotherapy or adjunctive therapy. This sNDA will be scrutinised under priority review, a mechanism whereby drugs may be approved more quickly, if they are found to offer significant improvement in the treatment of serious conditions, over currently available therapies. Following publication of results from a Phase III clinical trial [1], the FDA formally approved the use of paliperidone palmitate (trade named Invega Trinza) as a long-acting schizophrenia medication in May 2015. Invega Trinza has a dosing interval of three months.
Mechanism Of Action and Pharmacodynamic Effects
The most likely molecular mechanism of action (MMOA) of this drug is via antagonism of dopamine D2 and serotonin 5-HT2A receptors. The full MMOA remains to be determined.
External links